Boston Scientific Beats Expectations In Q1
Among the company's many milestones in the first quarter, the FDA approved its Therasphere radiation seed device, a major building block of the company's interventional oncology business.
You may also be interested in...
A new analysis from Wells Fargo found that the big medtech stocks typically perform at least as well as the overall market when inflationary expectations are high, but 2021 defied that trend.
COVID-19 continues to hinder Abbott’s heart failure and neuromodulation business, but sales of COVID-19 tests drove unprecedented growth in the diagnostics business.
The health care giant’s medical device revenues grew 8.8% in the first quarter, reflecting the recovery of interventions and surgeries since the start of the pandemic.